Candel Therapeutics, Inc. CADL
We take great care to ensure that the data presented and summarized in this overview for Candel Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CADL
View all-
Northpond Ventures, LLC1.94MShares$16.9 Million48.35% of portfolio
-
Vanguard Group Inc Valley Forge, PA946KShares$8.28 Million0.0% of portfolio
-
Black Rock Inc. New York, NY823KShares$7.2 Million0.0% of portfolio
-
State Street Corp Boston, MA492KShares$4.31 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA449KShares$3.93 Million0.0% of portfolio
-
Sands Capital Ventures, LLC Arlington, VA406KShares$3.55 Million1.45% of portfolio
-
Halter Ferguson Financial Inc. Carmel, IN305KShares$2.66 Million1.12% of portfolio
-
Northern Trust Corp Chicago, IL159KShares$1.39 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA135KShares$1.19 Million0.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX80.6KShares$705,2060.01% of portfolio
Latest Institutional Activity in CADL
Top Purchases
Top Sells
About CADL
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
Insider Transactions at CADL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 16
2024
|
Paul B Manning |
BUY
Open market or private purchase
|
Indirect |
1,250,000
+33.48%
|
$7,500,000
$6.0 P/Share
|
|
Dec 12
2024
|
Estuardo Aguilar Cordova > 10% Shareholder |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
200,000
-31.67%
|
$2,000,000
$10.04 P/Share
|
|
Dec 12
2024
|
Estuardo Aguilar Cordova > 10% Shareholder |
SELL
Sale (or disposition) back to the issuer
|
Direct |
200,000
-29.7%
|
$2,000,000
$10.04 P/Share
|
|
Dec 11
2024
|
Estuardo Aguilar Cordova > 10% Shareholder |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
200,000
-24.05%
|
$1,600,000
$8.53 P/Share
|
|
Dec 11
2024
|
Estuardo Aguilar Cordova > 10% Shareholder |
SELL
Sale (or disposition) back to the issuer
|
Direct |
200,000
-22.9%
|
$1,600,000
$8.53 P/Share
|
|
Dec 06
2024
|
Estuardo Aguilar Cordova > 10% Shareholder |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,000
-17.96%
|
$100,000
$5.23 P/Share
|
|
Dec 05
2024
|
Estuardo Aguilar Cordova > 10% Shareholder |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,000
-15.23%
|
$80,000
$4.79 P/Share
|
|
Dec 04
2024
|
Estuardo Aguilar Cordova > 10% Shareholder |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,000
-13.22%
|
$80,000
$4.46 P/Share
|
|
Nov 29
2024
|
Francesca Barone Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
22,081
-13.8%
|
$88,324
$4.56 P/Share
|
|
Nov 29
2024
|
William Garrett Nichols Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
13,935
-12.17%
|
$55,740
$4.56 P/Share
|
|
Nov 29
2024
|
Paul Peter Tak Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
48,847
-14.21%
|
$195,388
$4.56 P/Share
|
|
Nov 29
2024
|
Seshu Tyagarajan Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
20,392
-13.96%
|
$81,568
$4.56 P/Share
|
|
Nov 25
2024
|
Estuardo Aguilar Cordova > 10% Shareholder |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,000
-11.67%
|
$80,000
$4.97 P/Share
|
|
Nov 21
2024
|
Paul Peter Tak Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,900
+3.62%
|
$12,900
$1.55 P/Share
|
|
Nov 08
2024
|
Estuardo Aguilar Cordova > 10% Shareholder |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
7,500
-0.89%
|
$30,000
$4.92 P/Share
|
|
Nov 08
2024
|
Estuardo Aguilar Cordova > 10% Shareholder |
SELL
Sale (or disposition) back to the issuer
|
Direct |
7,500
-0.85%
|
$30,000
$4.92 P/Share
|
|
Nov 07
2024
|
Estuardo Aguilar Cordova > 10% Shareholder |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
7,500
-0.89%
|
$37,500
$5.19 P/Share
|
|
Nov 07
2024
|
Estuardo Aguilar Cordova > 10% Shareholder |
SELL
Sale (or disposition) back to the issuer
|
Direct |
7,500
-0.84%
|
$37,500
$5.19 P/Share
|
|
Nov 06
2024
|
Estuardo Aguilar Cordova > 10% Shareholder |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
7,500
-0.88%
|
$37,500
$5.33 P/Share
|
|
Nov 06
2024
|
Estuardo Aguilar Cordova > 10% Shareholder |
SELL
Sale (or disposition) back to the issuer
|
Direct |
7,500
-0.84%
|
$37,500
$5.33 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 1.25M shares |
|---|---|
| Open market or private sale | 6.21K shares |
| Exercise of conversion of derivative security | 12.9K shares |
| Open market or private sale | 312K shares |
|---|---|
| Sale (or disposition) back to the issuer | 998K shares |